Antiretroviral drug resistance in human immunodeficiency virus type 2.
about
Maraviroc: a review of its use in HIV infection and beyondHIV-1 Genetic Variability and Clinical ImplicationsFrequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, MozambiqueThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Genotypic resistance profiles of HIV-2-treated patients in West Africa.Re-testing and misclassification of HIV-2 and HIV-1&2 dually reactive patients among the HIV-2 cohort of the West African Database to evaluate AIDS collaborationThree main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimensAntiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsCell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsUpdate on human immunodeficiency virus (HIV)-2 infection.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.Clinical management of HIV drug resistance.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithmCombination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot.HIV-2 infection in Providence, Rhode Island from 2002 to 2011.Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strainsAcute Infections, Cost per Infection and Turnaround Time in Three United States Hospital Laboratories Using Fourth-Generation Antigen-Antibody Human Immunodeficiency Virus Immunoassays.The (5Z)-5-Pentacosenoic and 5-Pentacosynoic Acids Inhibit the HIV-1 Reverse Transcriptase.A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Novel inhibitors of human immunodeficiency virus type 2 infectivity.Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity.Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases.HIV testing updates and challenges: when regulatory caution and public health imperatives collide.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor Intolerance
P2860
Q26778504-8B83C476-79CE-4991-93DD-66F930BD341EQ30352010-20EE34F6-998D-4C10-9EBD-89A5D44B5074Q30406079-015C0E87-31C3-4199-99F8-235A1E530C1DQ33681279-E5427E01-95DE-46D5-8617-A6085B8BE5A0Q33954546-CDFFF077-EB53-4E9F-A74B-08F2D5DA1D97Q34052440-E4A372BF-A28A-467D-A3B1-6F850EF9D503Q34428902-2ECFFB78-3274-4BCE-8A2B-36B820E47D4EQ34730950-4967EF3A-3011-444D-B5B4-EE8E99489060Q34742090-556FDBE6-9641-424C-8E80-E17A1BF3F05FQ35019924-4DF43168-80E6-4609-B928-7400CAB0E90CQ35260403-D0831029-9C08-4C42-80B0-507821D2B40DQ35260590-DD3ED733-B483-4A05-B771-C7989F2B13B5Q35261045-5D55F9B1-798F-4428-A5AD-4A10F4BA8809Q35547048-21E1C0F3-E7E9-40DE-9BD9-94A731CB7594Q35878689-3A6851EC-05ED-4857-A71E-4A7C8F7AF01AQ35943486-F950E472-9272-4309-8F34-C10DE39500E5Q36077418-E0F4DFE3-0147-4209-AF8F-4DEAD5E5AECEQ36092039-B55B5A49-7701-40BC-9C7E-AAF0539C35D1Q36097686-F54C8476-25A8-425F-A7B2-1E6C34211D98Q36112849-88E765AA-3F55-4593-BB81-FF31497F8EF5Q36279208-867A3F7A-2A06-4D34-B7D3-20C1F80B4C34Q36358780-91A45A77-CC34-470A-AEE9-419BAA019F86Q36480450-D9C85310-F114-4046-BA63-E4C7876A36CEQ36826857-C7D697FE-B28D-4967-BA08-83AA75F925C7Q37512840-866AE293-F301-454A-81AB-103F977E7C8BQ37979703-92FBE0D6-8CD9-45D8-9379-6F9BCD3065BCQ38755690-5B31330C-A353-40CD-902C-B2FBC45669E1Q38967949-0D7B61FD-1000-49A5-AC08-B354658448E5Q39433148-335B1D67-E26E-400A-AD93-A7304AE3DDFEQ39533357-268E8F74-23DC-4DFD-9660-D984EFD491FCQ40267838-286D7A56-DE1E-4373-BA22-1BD74C5C1DF3Q40278530-3AB6E82C-64F6-41F3-A94C-570B3577F3B9Q41500321-F42B5FA2-F4A4-4AB9-A55A-24DA5C04F077Q47560712-9D536956-615D-4AFB-B851-5B3EAB90B16DQ58391480-F40C86A1-B019-4D6F-AA74-B0F9C5A49948
P2860
Antiretroviral drug resistance in human immunodeficiency virus type 2.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@en
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@nl
type
label
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@en
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@nl
prefLabel
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@en
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@nl
P2093
P2860
P356
P1476
Antiretroviral drug resistance in human immunodeficiency virus type 2.
@en
P2093
Bluma G Brenner
Mark A Wainberg
Thomas d'Aquin Toni
P2860
P304
P356
10.1128/AAC.00154-09
P407
P577
2009-05-26T00:00:00Z